Hepatocellular carcinoma: Occurrence, risk factors, biomarkers;Hepatocellularis carcinoma: Elofordulás, kórokok, biomarkerek

Orvosi Hetilap

Volumn 151, Issue 23, 2010, Pages 933-940

  Fehér, János ^a   Lengyel, Gabriella ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Alcohol; Hepatitis B virus; Hepatitis C virus; Hepatocellular carcinoma; Liver cirrhosis; Metabolic diseases; Non alcoholic steatohepatitis

Indexed keywords

BIOLOGICAL MARKER; MONOCLONAL ANTIBODY; SORAFENIB;

ALCOHOL CONSUMPTION; ALCOHOL LIVER DISEASE; ALPHA 1 ANTITRYPSIN DEFICIENCY; AUTOIMMUNE HEPATITIS; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; DIABETES MELLITUS; DISEASE COURSE; HEMOCHROMATOSIS; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; LIVER TRANSPLANTATION; NONALCOHOLIC FATTY LIVER; OBESITY; PATHOGENESIS; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; REVIEW; WILSON DISEASE;

EID: 77952790724     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: 10.1556/OH.2010.28900     Document Type: Review

References (41)

1. El-Serag, H. B., Andrew, C. M.: Rising incidence of hepatocellular carcinoma in the United States. N. Eng. J. Med., 1999, 340, 745-750.
2. El-Serag, H. B., Rudolph, K. L.: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology, 2007, 132, 2557-2576.
3. Parkin, D. M., Bray, F., Ferlay, J. es mtsa: Global cancer statistics, 2002. CA Cancer J. Clin., 2005, 55, 74-108.
4. Evans, T., Stein, C. (Eds): The World Health Report 2003. World Health Organisation, Geneva, 2003.
5. Feher J., Lengyel G. (szerk.): Hepatologia. Medicina Konyvkiado, Budapest, 2001.
6. Schutte, K., Bornschein, J., Malfertheiner, P.: Hepatocellular carcinoma - Epidemiological trends and risk factors. Dig. Dis., 2009, 27, 80-92.
7. Hassan, M. M., Hwang, L. Y., Hatten, C. J.: Risk factors for hepatocellular carcinoma: Synergis of alcohol with viral hepatitis and diabetes mellitus. Hepatology, 2002, 36, 1206-1213.
8. Hagymasi K., Tulassay Zs.: Az elsodleges majrak epidemiologiaja, koroka es kialakulasanak molekularis hattere. Orv. Hetil., 2008, 149, 541-548.
9. Blazovics A., Feher J.: Az oxidativ stressz es a maj. In: Hepatologia. Szerk.: Feher J., Lengyel G. Medicina Konyvkiado, Budapest, 2001, 50-88.
10. Klaunig, J. E., Xu, Y., Isenberg, J. S. es mtsai: The role of oxidative stress in chemical carcinogenesis. Environ Health Perspect., 1998, 106, 289-295.
11. Miura, H., Kawaguchi, T., Takazoe, M. es mtsai: Hepatocellular carcinoma and Crohn's disease: A case report and review. Inter. Med., 2009, 48, 815-819.
12. Al-Nozha, O. M., Ashgar, H. A., Khan, M. es mtsa: Hepatocellular carcinoma in the abscence of liver cirrhosis in a treated hepatitis C virus patient. Ann. Saudi Med. J., 2009, 29, 235-236.
13. Jozsa L., Ikrenyi I., Luszig G.: Elsodleges majrak 6 hetes csecsemoben. Gyermekgyogyaszat, 1964, 15, 155-158.
14. Rigamonti, C., Mottaran, E., Reale, E. es mtsai: Moderate alcohol consumption increases oxidative stress in patients with chronic hepatitis C. Hepatology, 2003, 38, 42-49.
15. Wiley, T. E., McCarthy, M., Breidi, L. es mtsai: Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology, 1998, 28, 805-809.
16. Par A., Par G.: Majfibrosis, pathophysiologia es kezeles. Orv. Hetil., 2005, 146, 3-13.
17. Hwai-I Yang, Sheng-Nan Lu, Yun-Fan Liaw es mtsai: Hepatitis B e antigen and the risk of hepatocellular carcinoma. N. Eng. J. Med., 2002, 347, 168-174.
18. Hassan, M. M., Hwang, L. Y., Hatten, C. J.: Risk factors for hepatocellular carcinoma: Synergis of alcohol with viral hepatitis and diabetes mellitus. Hepatology, 2002, 36, 1206-1213.
19. Sherman, M.: Risk of hepatocellular carcinoma in hepatitis B and prevention through treatment. Clev. Clin. J. Med. 2009, 76, S6-S9.
20. Baffis, V., Shrier, I., Sherker, A. H. es mtsa: Use of interferon for prevention of hepatocellular carcinoma in cirrhotic patients with hepatitis B or hepatitis C virus infection. Ann. Intern. Med., 1999, 131, 696-701.
21. Angelico, F., Del Ben, M., Conti, R. es mtsa: Non-alcoholic fatty liver syndrome: A hepatic consequence of common metabolic diseases. J. Gastroenterol. Hepatol., 2003, 18, 1115-1117.
22. Feher, J., Lengyel, G.: A new approach to drug therapy in nonalcoholic steatohepatitis (NASH). J. Intern. Med. Research, 2003, 31, 537-551.
23. Fraenkel E., Lazurova, I., Feher J.: A lipidperoxidacio szerepe a nem alkoholos steatohepatitis kialakulasaban. Orv. Hetil., 2004, 145, 611-618.
24. Regimbeau, J. M., Colombat, M., Mognol, P. es mtsa: Obesity and diabetes as a risk factor for hepatocellular carcinoma. Liver Transpl., 2004, 10, S69-S73.
25. Sanyal, A. J., Contos, M. J., Sterling, R. K. es mtsai: Nonalcoholic fatty liver disease in patients with hepatitis C is associated with features of the metabolic syndrome. Am. J. Gastroenterol., 2003, 98, 2064-2071.
26. Luyckx, F. H., Lefebvre, P. J., Scheen, A. J.: Non-alcoholic steatohepatitis: association with obesity and insulin resistance, and influence of weight loss. Diab. Metabol., 2000, 26, 98-106.
27. Pagano, G., Pacini, G., Musso, G. es mtsai: Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: Further evidence for an etiologic association. Hepatology, 2002, 35, 367-372.
28. Willner, I. R., Waters, B., Patil, S. R. es mtsa: Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease. Am. J. Gastroenterol., 2001, 96, 2813-2814.
29. Bishayee, A., Dhir, N.: Resveratrol-mediated chemoprevention of diethylnitrosamine-initiated hepatocarcinogenesis: inhibition of cell proliferation and induction of apoptosis. Chem. Biol. Interact., 2009, 179, 131-144.
30. Gomaa, A. I., Khan, S. A., Leen, E. L. S. es mtsai: Diagnosis of hepatocellular carcinoma. World J. Gastroenterol., 2009, 15, 1301-1314.
31. Kaposi-Novak P.: Az emberi majrak komparativ genomikai osztalyozasa. Magyar Onkologia, 2009, 53, 61-67.
32. Saito, H., Masuda, T., Tada, S. es mtsai: Hepatocellular carcinoma in Keio Affiliated Hospitals - Diagnosis, treatment, and prognosis of this disease. Keio J. Med., 2009, 58, 161-175.
33. Rampone, B., Schiavone, B., Martino, A. es mtsai: Current management strategy of hepatocellular carcinoma. World J. Gastroenterol., 2009, 15, 3210-3216.
34. Abou-Alfa, G. K., Huitzil-Melendez, F-D., O'Reilly, E. M. es mtsai: Current management of advanced hepatocellular carcinoma. Gastrointest. Cancer Res., 2008, 2, 64-70.
35. Szalay F.: Uj aspektusok a majrak kezeleseben. Haziorvos Tovabbkepzo Szemle, 2009, 14, 442-444.
36. Horvath-Karajz K., Sreter, L.: A majrak szisztemas kemoterapiaja es a betegek gondozasa. Orv. Hetil., 2004, 145, 405-407.
37. Seufi , A. M., Ibrahim, S. S., Elmaghraby, T. K. es mtsai: Preventive effect of the flavonoid, quercetin, on hepatic cancer in rats via oxidant/antioxidant activity: molecular and histological evidences. J. Exp. Clin. Cancer Res., 2009, 28, 80-88.
38. Feher, J., Lengyel, G.: Silymarin in the treatment of chronic liver diseases: Past and future. Clin. Exp. Med. J., 2009, 3, 403-413.
39. Spangenberg, H. C., Thimme, R., Blum, H. E.: Targeted therapy for hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol., 2009, 6, 423-432.
40. Dank M.: A primer majrak barcelonai stadiumbeosztasanak prognosztikai es terapias jelntosege. LAM, 2008, 18, 369-372.
41. Bouattour, M., Marijon, H., Dreyer, C. es mtsai: Targeted therapies in hepatocellular carcinoma. [Article in French] Presse Med., 2010 Apr 6. (Epub ahead of print)